SCHEMBL5881987

SCHEMBL5881987

Cc1[nH]c2ccc(C(=O)NS(=O)(=O)/C=C/c3ccccc3)cc2c1Cc1ccc(-c2ccccc2)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
PTGS2 P35354 1/20 0.39
SCN9A Q15858 1/20 0.38
TP53 P04637 2/20 0.37
PTPN5 P54829 1/20 0.37
MCL1 Q07820 3/20 0.35
POLB P06746 1/20 0.35
PPARG P37231 1/20 0.35
HDAC8 Q9BY41 3/20 0.35
HDAC6 Q9UBN7 3/20 0.35
HDAC3 O15379 2/20 0.35
HDAC4 P56524 2/20 0.35
HDAC1 Q13547 2/20 0.35
HDAC7 Q8WUI4 2/20 0.35
HDAC2 Q92769 2/20 0.35
HDAC10 Q969S8 2/20 0.35
HDAC11 Q96DB2 2/20 0.35
HDAC9 Q9UKV0 2/20 0.35
HDAC5 Q9UQL6 2/20 0.35
SNCA P37840 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5882071 0.91 MAPT (0.42) MAPTPTGS2TP53PTPN5MCL1
SCHEMBL5882069 0.91 MAPT (0.42) MAPTPTGS2TP53PTPN5MCL1
SCHEMBL6135076 0.90 MAPT (0.41) MAPTPTGS2TP53PTPN5POLB
SCHEMBL6135073 0.90 MAPT (0.41) MAPTPTGS2TP53PTPN5POLB
SCHEMBL6318588 0.88 SCN5A (0.40) MAPTPTGS2SCN9ATP53PTPN5
SCHEMBL6319284 0.88 SCN5A (0.40) MAPTPTGS2SCN9ATP53PTPN5
SCHEMBL5881622 0.87 MAPT (0.46) MAPTPTGS2MCL1HDAC8HDAC6
SCHEMBL5881755 0.85 PTPN1 (0.48) MAPTPTGS2TP53MCL1PPARG
SCHEMBL5881759 0.85 PTGS2 (0.46) MAPTPTGS2MCL1HDAC8HDAC6
SCHEMBL6320933 0.85 MAPT (0.40) MAPTPTGS2SCN9ATP53PTPN5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7115647-B2 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. (US) 2006-10-03 US disclosed
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives OSI PHARMACEUTICALS, INC. 2002-10-03 US disclosed
US-6410584-B1 ANTICANCER AGENTS CELL PATHWAYS, INC. 2002-06-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143022-A1 Method of inhibiting neoplastic cells with indole derivatives IDO1, IDO2, INMT MAPT 4038/4885PTGS2 230/4885SCN9A 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.